Egypt received a new shipment of 1.8 million Pfizer coronavirus vaccines donated by the United States on Saturday night via the COVID-19 Vaccines Global Access program (COVAX) and the Vaccine Alliance (GAVI), the Ministry of Health and Population announced.
The US embassy in Cairo stated on Saturday that Egypt has so far received 10 vaccine shipments comprising more than 21 million doses of high-quality US vaccines since 1 September 2021.
The new shipment come from a 500-million Pfizer vaccine inventory that the US is distributing to African Union (AU) countries through COVAX.
Egypt has been using the Pfizer vaccine in its mass vaccination campaign along with several other vaccines.
It has also designated the Pfizer jab for inoculating youngsters aged 12 to 18.
Egypt tops Africa in coronavirus vaccine stock, which includes all currently available vaccines worldwide — the Chinese Sinopharm and Sinovac, the British-Swedish AstraZeneca, the Russian Sputnik V, and the US-made Moderna, Pfizer, and Johnson&Johnson vaccines.
Egypt has obtained a total of 132 million vaccines, administering 36.6 million vaccines as first doses and 24.1 million as second doses, according to Khaled Abdel-Ghaffar, the acting health minister.
Abdel-Ghaffar also announced recently that 489,700 booster shots have also been administered, bringing the total number of jabs administered to the public to 61.3 million.
Distributed by APO Group on behalf of Official Portal of Cairo Governorate.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
